Yolkin Isolated from Hen Egg Yolk as a Natural Immunoregulator, Activating Innate Immune Response in BMDM Macrophages
Wioletta Kazana , Małgorzata Mitkiewicz , Michał Ochnik , M. Sochocka , Aleksandra Zambrowicz , G. Piechowiak , Józefa Macała , Paulina Miernikiewicz , Agnieszka Zabłocka
AbstractOne of the goals of biomedical sciences is to search and identify natural compounds that are safe, have no side effects, and possess immunostimulatory activity. It has been proven that medicines of natural origin can be effective agents, supporting the therapy of many diseases, not only in the weakened immune system of the body but also in the prevention of many diseases in healthy people. It has been shown that yolkin, a polypeptide complex isolated from hen egg yolk as a fraction accompanying immunoglobulin Y (IgY), possesses potential biological activity. However, the mechanism of its action has not been explained. The objective of this investigation was to examine the molecular mechanisms of innate immune response, activated in response to yolkin, in murine bone marrow-derived macrophages (BMDM). It was shown that yolkin induced phosphorylation of extracellular signal-kinases (ERK1/2) and c-Jun N-terminal kinase (JNK) and upregulated expression and production of type I interferons, TNF-α(tumor necrosis factorα), and nitric oxide (NO), in BMDM cells. Using pharmacological inhibitors of ERK 1/2 and JNK kinases, we revealed that the JNK signaling cascade is required for yolkin-induced inducible NOS expression and upregulation of NO production in mouse macrophages. Using the TLR4-deficient BMDM cell line, we established that yolkin can activate macrophages in a TLR4-dependent manner. It was also shown that NO, TNF-α, and type I IFNs (α/β) produced by BMDM cells in response to yolkin triggered antiviral activity. These data indicate that yolkin affects the regulation of the immune system and antiviral response; therefore, it can be used as an effective immunostimulator of the innate immunity or as a supplement of the conventional therapy of immunodeficiency.
|Journal series||Oxidative Medicine and Cellular Longevity, ISSN 1942-0900, e-ISSN 1942-0994, (N/A 100 pkt)|
|Publication size in sheets||0.65|
|ASJC Classification||; ; ;|
|License||Journal (articles only); published final; ; with publication|
|Score||= 100.0, 15-09-2020, ArticleFromJournal|
|Publication indicators||: 2017 = 1.315; : 2018 = 4.868 (2) - 2018=5.392 (5)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.